Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.36 |
| ▸ | NQO2 | P16083 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693683 | 0.85 | LMNA (0.55) | KMT2ACYP1A2LMNATDP1ALDH1A1 | |
| SCHEMBL105629 | 0.85 | LMNA (0.55) | KMT2ACYP1A2LMNATDP1ALDH1A1 | |
| SCHEMBL784628 | 0.85 | LMNA (0.42) | MAPTMEN1TSHRKMT2AATM | |
| SCHEMBL6118304 | 0.84 | MAPT (0.39) | MAPTMEN1TSHRKMT2AATM | |
| SCHEMBL10846333 | 0.82 | SMN1; SMN2 (0.36) | MAPTMEN1TSHRKMT2AATM | |
| Hydrochloric Acid SCHEMBL11420669 | 0.82 | MAPT (0.38) | MAPTMEN1TSHRKMT2AATM | |
| SCHEMBL12570771 | 0.80 | NOS3 (0.34) | MAPTMEN1TSHRKMT2AATM | |
| SCHEMBL26698986 | 0.80 | MAPT (0.38) | MAPTMEN1TSHRKMT2AATM | |
| SCHEMBL798987 | 0.80 | ALDH1A1 (0.39) | MAPTMEN1TSHRKMT2AATM | |
| SCHEMBL4648295 | 0.79 | MAPT (0.41) | MAPTMEN1TSHRKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119100997-A | Sulfadiol preparation method of octyl | 重庆康乐制药有限公司 | 2024-12-10 | — | — | CN | claimed |
| EP-2170837-B1 | PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL)-PHENYL)-2-METHYLPROPIONIC ACID | SANOFI SA (FR) | 2011-11-02 | — | — | EP | claimed |
| US-20100184979-A1 | NEW PROCESS FOR PREPARING 2-(3--PHENYL)-2-METHYLPROPRIONIC ACID | SANOFI-AVENTIS (FR) | 2010-07-22 | — | — | US | claimed |
| EP-2170837-A2 | PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL)-PHENYL)-2-METHYLPROPIONIC ACID | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | claimed |
| WO-2009006086-A2 | A NEW PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL}-PHENYL)- 2-METHYLPROPIONIC ACID | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | claimed |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | RECURSION PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| CN-119100997-A | Sulfadiol preparation method of octyl | 重庆康乐制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-119100997-A | Sulfadiol preparation method of octyl | 重庆康乐制药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-12157737-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2024-12-03 | — | — | US | disclosed |
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-07-25 | — | — | US | disclosed |
| US-6875830-B2 | Chelating pyrimidines as ligands for single-site olefin polymerization catalysts | EQUISTAR CHEMICALS, LP (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1231211-B1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTIDIABETIC AGENTS | VITA INVEST SA (ES) | 2003-05-28 | — | — | EP | disclosed |
| US-20030013823-A1 | CHELATING PYRIMIDINES AS LIGANDS FOR SINGLE-SITE OLEFIN POLYMERIZATION CATALYSTS | EQUISTAR CHEMICALS, LP | 2003-01-16 | — | — | US | disclosed |
| US-20030008987-A1 | Chelating pyrimidines as ligands for single-site olefin polymerization catalysts | EQUISTAR CHEMICALS, L.P. | 2003-01-09 | — | — | US | disclosed |
| WO-2002098931-A1 | CHELATING PYRIMIDINES AS LIGANDS FOR SINGLE-SITE OLEFIN POLYMERIZATION CATALYSTS | EQUISTAR CHEMICALS, LP (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6489414-B1 | THE CATALYST SYSTEM COMPRISES AN OPTIONAL ACTIVATOR AND A COMPLEX THAT INCORPORATES A GROUP 3 TO 10 TRANSITION METAL AND AT LEAST ONE NEUTRAL OR ANIONIC CHELATING PYRIMIDINE LIGAND. THE LIGANDS ARE EASY TO MAKE, AND THEY ARE READILY | EQUISTAR CHEMICALS, LP | 2002-12-03 | — | — | US | disclosed |
| EP-1231211-A1 | THIAZOLIDINEDIONE DERIVATIVES AS ANTIDIABETIC AGENTS | VITA-INVEST, S.A. (ES) | 2002-08-14 | — | — | EP | disclosed |
| WO-1993005011-A1 | NOVEL IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184979-A1 | NEW PROCESS FOR PREPARING 2-(3--PHENYL)-2-METHYLPROPRIONIC ACID | DCPS, HPD, PAH | MAPT 3305/4885MEN1 658/4885TSHR 3138/4885 |
| US-20260138956-A1 | NOVEL COMPOUNDS AND USES THEREOF | SLC10A1, NR3C2, CYP2C8 | MAPT 3402/4885MEN1 2549/4885TSHR 1393/4885 |
| US-12157737-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | MAPT 4450/4885MEN1 1544/4885TSHR 904/4885 |
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | PLA2G1B, LYPLAL1, PLA2G12B | MAPT 4463/4885MEN1 1759/4885TSHR 3502/4885 |
| US-20250092042-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, PKD1, PKD2 | MAPT 4190/4885MEN1 1485/4885TSHR 608/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | MAPT 4485/4885MEN1 4873/4885TSHR 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.